60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Go back to 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue| (NASDAQ: SXTP) | Delayed: 1.49 -0.06 (3.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.55 | 52 Week High | $ | |||
| Open | $1.51 | 52 Week Low | $ | |||
| Day High | $1.62 | P/E | N/A | |||
| Day Low | $1.47 | EPS | $ | |||
| Volume | 25,611 | |||||
| (NASDAQ: SXTPW) | Delayed: 0.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.03 | 52 Week High | $ | |||
| Open | $0.03 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.03 | EPS | $ | |||
| Volume | 218,909 | |||||
